Global private equity and venture capital news and research

Fibrotec leads $22m Series D for therapeutics company Promedior

8 Mar 2012

blood-cells_sqPromedior, a clinical stage biotechnology company that develops therapeutics for the treatment of fibroproliferative diseases, has raised $22m in the first closing of a Series D financing round led by a new investor Fibrotec Ventures.

Sorry, to get access to this you need to subscribe for free.

In order to view more content, sign-up to our free daily newsletter.

If you would like to read the premium stories, have complete access to our breaking news and Limited Partner magazine you need to become a Premium Subscriber.

Subscribe to AltAssets today

Login to AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016